Company Encyclopedia
View More
name
China Meheco
600056.SH
China Meheco Group Co., Ltd. engages in the manufacture, marketing, and trade of pharmaceuticals and medical devices in China and internationally. The company is involved in the planting and sale of Chinese medicinal materials, as well as the provision of related technical and warehousing services. Its drug products cover therapeutic fields, such as anti-infection, cardiovascular, hormones and endocrine regulation, respiratory and digestive systems, nutritional supplements, antipyretic analgesics, and other therapeutic areas as well as Chinese herbal medicine processing and decoction pieces.
400.42 B
600056.SHMarket value -Rank by Market Cap -/-

Financial Score

09/12/2025 Update
C
Health Care DistributorsIndustry
Industry Ranking6/25
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE4.37%C
    • Profit Margin1.54%C
    • Gross Margin10.43%E
  • Growth ScoreD
    • Revenue YoY-7.27%D
    • Net Profit YoY-44.85%D
    • Total Assets YoY-2.35%D
    • Net Assets YoY1.43%C
  • Cash ScoreC
    • Cash Flow Margin6473.56%A
    • OCF YoY-7.27%D
  • Operating ScoreB
    • Turnover0.89B
  • Debt ScoreD
    • Gearing Ratio61.36%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    China Meheco: Subsidiary Tianfang Pharmaceutical's Nicardipine Tablets intend to be selected for the 11th batch of national centralized drug procurement

    China Meheco's subsidiary Tianfang Pharmaceutical Co., Ltd. participated in the bidding for the 11th batch of national centralized drug procurement, with its Nicardipine tablets expected to be selected, specifications of 5mg, priced at 2.59 yuan/box, with a procurement period of 3 years. Tianfang Pharmaceutical's audited operating income for 2024 is approximately 52.47 million yuan. If successful in the bid, it will help expand sales scale, increase market share, and have a positive impact on the company's future performance

    Zhitong·
    SH
    600056
    -1.38%
    Zhitong·
    SH
    600056
    -1.38%

    China Meheco's 3 billion ultra-short-term financing bond registration accepted by the Association of Dealers

    On May 16, 2025, China Meheco Health Industry Co., Ltd. approved the proposal on "Conducting Company Bond and Super Short-term Financing Bond Registration" at the 2024 Annual Shareholders' Meeting. Recently, the company received the "Registration Acceptance Notice" from the National Association of Financial Market Institutional Investors, accepting its super short-term financing bond registration amount of 3 billion yuan, with a registration validity of 2 years, co-led by 7 banks including China Merchants Bank and Industrial and Commercial Bank of China. The company may issue in installments during the registration validity period, and will disclose the results after the issuance is completed, fulfilling its information disclosure obligations as required

    Zhitong·
    SH
    600056
    -1.38%
    Zhitong·
    SH
    600056
    -1.38%

    China Meheco signed a strategic cooperation framework agreement with the Faku County Government

    On September 24th, China Meheco signed a strategic cooperation framework agreement with the government of Faku County. According to the agreement, both parties will carry out in-depth cooperation in areas such as the development of the pharmaceutical and healthcare industry and empowering the construction of closely-knit county-level medical communities

    Zhitong·
    SH
    600056
    -1.38%
    Zhitong·
    SH
    600056
    -1.38%

    China Meheco's Unit Gets Nod for Supplementary Application for Lincomycin Hydrochloride Injection After Passing Evaluation

    (MT Newswires) -- China Meheco Group's (SHA:600056) unit, Tianfang Pharmaceutical, received approval from the Chinese drug administrator for its drug supplementary application for lincomycin hydrochloride injection after the drug passed regulatory evaluation, according to a Shanghai bourse filing on Wednesday. The drug, which is mainly used for the treatment of severe infections caused by susceptible strains such as streptococci, pneumococci, and staphylococci, was tested for its consistency in quality and efficiency. The Chinese drugmaker's shares dropped less than 2% during the afternoon trade.

    marketscreener·
    SH
    600056
    -1.38%
    marketscreener·
    SH
    600056
    -1.38%

    Some domestic and foreign investment institutions visited the National Healthcare Security Administration

    On September 19th, Temasek Holdings and other investment institutions visited the National Healthcare Security Administration to discuss healthcare support for the high-quality development of China Meheco. The National Healthcare Security Administration stated that it will continue to implement relevant policies, utilize healthcare funds, policies, and data resources to promote the development of pharmaceutical institutions and drug innovation, and welcome domestic and foreign investment institutions to pay attention to the Chinese pharmaceutical industry. Participating institutions included AXA Investment Managers, Temasek Holdings, and others

    Zhitong·
    SH
    600056
    -1.38%
    Zhitong·
    SH
    600056
    -1.38%
    © 2025 Longbridge｜Disclaimer